Literature DB >> 517881

Passive-active immunity from hepatitis B immune globulin. Reanalysis of a Veterans Administration cooperative study of needle-stick hepatitis. The Veterans Administration Cooperative Study Group.

J H Hoofnagle, L B Seeff, Z B Bales, E C Wright, H J Zimmerman.   

Abstract

The mechanism of action of hepatitis B immune globulin (HBIG) and immune serum globulin was sought in a reanalysis of a Veterans Administration cooperative study on needle-stick exposure to hepatitis B surface antigen (HBsAg)-positive blood. Sera from 296 exposed persons were tested for HBsAg, antibody to HBsAg (anti-HBs), and antibody to hepatitis B core antigen (anti-HBc) by radioimmunoassay. Type B hepatitis developed in three HBIG (2%) and in 12 ISG (8%) recipients. In contrast, subclinical infection (development of HBsAg or anti-HBs and anti-HBc without symptoms or jaundice) developed in 16 HBIG (10%) but only six immune serum globulin (4%) recipients. Thus, infection occurred equally in both groups but was more likely to be subclinical in HBIG recipients, indicating that HBIG permitted development of passive-active immunity to type B hepatitis. An additional 53 immune serum globulin recipients (36%) but only one HBIG recipient developed anti-HBs alone, without hepatitis, HBsAg, or anti-HBc. This response was more compatible with immunization by HBsAg than with infection. Ultracentrifugation analysis revealed occult HBsAg in the immune serum globulin but not the HBIG, indicating that some immune serum globulin preparations contain HBsAg and can induce active immunity to type B hepatitis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 517881     DOI: 10.7326/0003-4819-91-6-813

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

Review 1.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 2.  Nosocomial spread of viral disease.

Authors:  C Aitken; D J Jeffries
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

3.  The hepatitis B vaccine: utilization decision process and outcomes in community hospitals.

Authors:  B Kirkman-Liff; S Dandoy; G Kallet
Journal:  Health Serv Res       Date:  1985-06       Impact factor: 3.402

4.  Use of immunoglobulin with high content of antibody to hepatitis B surface antigen (anti-HBs). Working Party on the Clinical Use of Specific Immunoglobulin in Hepatitis B.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-02

5.  Risk of infection from needle reuse at a phlebotomy center.

Authors:  T C Porco; T J Aragón; S E Fernyak; S H Cody; D J Vugia; M H Katz; D R Bangsberg
Journal:  Am J Public Health       Date:  2001-04       Impact factor: 9.308

6.  What is the dentist's occupational risk of becoming infected with hepatitis B or the human immunodeficiency virus?

Authors:  E I Capilouto; M C Weinstein; D Hemenway; D Cotton
Journal:  Am J Public Health       Date:  1992-04       Impact factor: 9.308

7.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

8.  Simultaneous acute infections with hepatitis non-A, non-B, and B viruses.

Authors:  Y F Liaw; C M Chu; C S Chang-Chien; C S Wui
Journal:  Dig Dis Sci       Date:  1982-08       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.